CHA Biotech Co. Ltd (085660) — Cash Flow-to-Debt Ratio
CHA Biotech Co. Ltd (085660) has a Cash Flow-to-Debt Ratio of -0.04x as of March 2026, meaning its operating cash flow of ₩-64.01 Billion could theoretically repay 0% of its total liabilities (₩1.77 Trillion) in one year. See 085660 financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
CHA Biotech Co. Ltd Cash Flow-to-Debt Ratio (2009–2025)
Historical debt coverage capacity for CHA Biotech Co. Ltd across 17 annual periods. For the full cash flow conversion analysis, see 085660 cash flow conversion.
Annual Cash Flow-to-Debt Ratio for CHA Biotech Co. Ltd (2009–2025)
Year-by-year debt coverage analysis for CHA Biotech Co. Ltd. Check 085660 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.04x | ₩-72.52 Billion | ₩1.74 Trillion | ▼ -60.8% |
| 2024 | -0.03x | ₩-49.55 Billion | ₩1.91 Trillion | ▼ -341.0% |
| 2023 | 0.01x | ₩11.51 Billion | ₩1.07 Trillion | ▲ +168.6% |
| 2022 | -0.02x | ₩-20.63 Billion | ₩1.32 Trillion | ▼ -176.1% |
| 2021 | 0.02x | ₩22.23 Billion | ₩1.08 Trillion | ▼ -58.0% |
| 2020 | 0.05x | ₩47.00 Billion | ₩958.62 Billion | ▲ +52.6% |
| 2019 | 0.03x | ₩25.24 Billion | ₩785.74 Billion | ▼ -73.6% |
| 2018 | 0.12x | ₩75.38 Billion | ₩620.54 Billion | ▲ +469.4% |
| 2017 | 0.02x | ₩12.01 Billion | ₩562.87 Billion | ▼ -8.8% |
| 2016 | 0.02x | ₩11.29 Billion | ₩482.61 Billion | ▼ -86.6% |
| 2015 | 0.17x | ₩61.86 Billion | ₩354.73 Billion | ▲ +1345.7% |
| 2014 | -0.01x | ₩-2.57 Billion | ₩183.43 Billion | ▼ -103.7% |
| 2013 | 0.38x | ₩66.35 Billion | ₩173.12 Billion | ▲ +56.6% |
| 2012 | 0.24x | ₩45.77 Billion | ₩187.06 Billion | ▲ +33.7% |
| 2011 | 0.18x | ₩34.69 Billion | ₩189.56 Billion | ▼ -23.4% |
| 2010 | 0.24x | ₩42.07 Billion | ₩176.06 Billion | ▲ +2.2% |
| 2009 | 0.23x | ₩24.02 Billion | ₩102.75 Billion | — |